UroGen Pharma is trading 4.1% down at $43.62, with no clear company-specific catalyst identified for August 28, 2026.

  • Latest disclosures were the August 20 IntraGel collaboration and August 17 UGN-103 NDA submission, both predating the move.
  • The Nasdaq Composite is down 0.33%, so broader market weakness alone does not clearly explain the sharper decline.
  • Trading-volume data was unavailable, leaving the immediate catalyst uncertain.